Antibodies which bind to epithelial membrane protein 2 (EMP2)

Patent metadata

Field	Value
Publication number	US-9624304-B2
Application number	US-201514666091-A
Country	US
Kind code	B2
Filing date	Mar 23, 2015
Priority date	Apr 15, 2005
Publication date	Apr 18, 2017
Grant date	Apr 18, 2017

Abstract

The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.

First claim

What is claimed is:

1. An isolated antibody that competes for binding to the extracellular loop of human Epithelial Membrane Protein 2 (EMP2) (SEQ ID NO: 42) with an EMP2 inhibitor, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises three heavy chain complementary determining regions (HCDRs) and wherein the light chain variable region comprises three light chain variable regions (LCDRs), wherein:

the sequence of HCDR1 is EYPMH (SEQ ID NO: 15),

the sequence of HCDR2 is VISYDGEYQKYADSVKG (SEQ

ID NO: 17),

the sequence of HCDR3 is TINNGMDV (SEQ ID NO: 41),

the sequence of LCDR1 is RASQGIRNDLG (SEQ ID NO:

20),

the sequence of LCDR2 is GASSLQS (SEQ ID NO: 23),

and

the sequence of LCDR3 is LQDYNGWT (SEQ ID NO: 40).

2. The antibody of claim 1 , wherein the antibody is a monoclonal antibody, a humanized monoclonal antibody, a human antibody, a diabody, minibody, or triabody, a chimeric antibody, or a recombinant antibody.

3. The antibody of claim 1 , wherein the antibody is in an scFv, minibody, diabody, or triabody format.

4. The antibody of claim 1 , wherein the antibody is conjugated to a cytotoxic agent or a label.

5. A pharmaceutical composition comprising the antibody of claim 1 and a physiologically acceptable carrier.

6. An isolated antibody which binds to Epithelial Membrane Protein 2 (EMP2), wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises three heavy chain complementary determining regions (HCDRs) and wherein the light chain variable region comprises three light chain complementary determining regions (LCDRs), wherein:

the sequence of HCDR1 is EYPMH (SEQ ID NO: 15),

the sequence of HCDR2 is VISYDGEYQKYADSVKG (SEQ

ID NO: 17),

the sequence of HCDR3 is TINNGMDV (SEQ ID NO: 41),

the sequence of LCDR1 is RASQGIRNDLG (SEQ ID NO:

20),

the sequence of LCDR2 is GASSLQS (SEQ ID NO: 23),

and

the sequence of LCDR3 is LQDYNGWT (SEQ ID NO: 40).

7. The antibody of claim 6 , wherein the antibody is a monoclonal antibody, a humanized monoclonal antibody, a human antibody, a diabody, minibody, or triabody, a chimeric antibody, or a recombinant antibody.

8. The antibody of claim 6 , wherein the antibody is in an scFv, minibody, diabody, or triabody format.

9. The antibody of claim 6 , wherein the antibody is conjugated to a cytotoxic agent or a label.

10. A pharmaceutical composition comprising the antibody of claim 6 and a physiologically acceptable carrier.

Assignees

• Univ California

Inventors

• Braun Jonathan
• Gordon Lynn K
• Dadgostar Kaori Shimazaki
• Wadehra Madhuri
• Kelly Kathy A
• Wu Anna M

Classifications

• C07K2317/21

  from primates, e.g. man · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title

• C07K16/28

  against receptors, cell surface antigens or cell surface determinants · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title

• C07K2317/622

  Single chain antibody (scFv) · CPC title